Novavax reported $185.92M in Sales Revenues for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Adma Biologics ADMA:US $ 33.9M 4.8M
Agenus AGEN:US $ 20.93M 5.01M
AstraZeneca AZN:LN 10771M 619M
Astrazeneca AZN:US $ 10771M 619M
Biocryst Pharmaceuticals BCRX:US $ 65.53M 15.61M
Dynavax Technologies DVAX:US $ 256.46M 142.47M
Genocea Biosciences GNCA:US $ 0.27M 0.27M
Geron GERN:US $ 0.07M 0.05M
GlaxoSmithKline GSK:LN 6929M 2851M
Mannkind MNKD:US $ 18.89M 6.9M
Merk MRK:US $ 14593M 1308M
Moderna Inc MRNA:US 4.75B 1.32B
Novartis NVS:US $ 13085M 271M
Novavax NVAX:US $ 185.92M 518.05M
Peregrine Pharmaceuticals PPHM:US $ 31.23M 0.28M
Pfizer PFE:US $ 27742M 2081M
Sarepta Therapeutics SRPT:US $ 233.49M 22.66M
Tg Therapeutics TGTX:US $ 0.59M 1.42M